文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Mendonça R Z, Ioshimoto L M, Mendonça R M, De-Franco M, Valentini E J, Beçak W, Raw I, Pereira C A

Instituto Butantan, São Paulo, Brasil.

Braz J Med Biol Res. 1993 Dec;26(12):1305-17.

The rabies virus (Pasteur PV strain) was propagated in VERO cells attached to microcarriers in a 3.7-1 bioreactor. Virus titers of about 10(6) LD50/ml were obtained regularly. 2. Ultrafiltration was efficient for concentrating the virus suspensions, and the sucrose gradient reduced the residual VERO cell DNA to acceptable levels (less than 50 pg/dose). The remaining cell DNA content was evaluated by dot-blot hybridization with a probe prepared with VERO cell DNA. 3. The final virus preparations were inactivated by B-propiolactone treatment, showed a potency higher than 2.5 IU/dose and protected mice experimentally infected intracerebrally with rabies virus (CVS-13.2). 4. This methodology for the production of a rabies vaccine for human use should be of interest to countries where high technology facilities are not available.

狂犬病病毒（巴斯德PV株）在3.7升生物反应器中附着于微载体的VERO细胞中增殖。定期获得约10(6) LD50/ml的病毒滴度。2. 超滤对浓缩病毒悬液有效，蔗糖梯度将残留的VERO细胞DNA降低到可接受水平（低于50 pg/剂量）。通过用VERO细胞DNA制备的探针进行斑点印迹杂交来评估剩余的细胞DNA含量。3. 最终的病毒制剂通过β-丙内酯处理灭活，效力高于2.5 IU/剂量，并能保护经脑内接种狂犬病病毒（CVS-13.2）实验感染的小鼠。4. 这种用于生产人用狂犬病疫苗的方法对于没有高科技设施的国家应该是有意义的。

Mendonça R Z, Ioshimoto L M, Mendonça R M, De-Franco M, Valentini E J, Beçak W, Raw I, Pereira C A

Instituto Butantan, São Paulo, Brasil.

Braz J Med Biol Res. 1993 Dec;26(12):1305-17.

The rabies virus (Pasteur PV strain) was propagated in VERO cells attached to microcarriers in a 3.7-1 bioreactor. Virus titers of about 10(6) LD50/ml were obtained regularly. 2. Ultrafiltration was efficient for concentrating the virus suspensions, and the sucrose gradient reduced the residual VERO cell DNA to acceptable levels (less than 50 pg/dose). The remaining cell DNA content was evaluated by dot-blot hybridization with a probe prepared with VERO cell DNA. 3. The final virus preparations were inactivated by B-propiolactone treatment, showed a potency higher than 2.5 IU/dose and protected mice experimentally infected intracerebrally with rabies virus (CVS-13.2). 4. This methodology for the production of a rabies vaccine for human use should be of interest to countries where high technology facilities are not available.

狂犬病病毒（巴斯德PV株）在3.7升生物反应器中附着于微载体的VERO细胞中增殖。定期获得约10(6) LD50/ml的病毒滴度。2. 超滤对浓缩病毒悬液有效，蔗糖梯度将残留的VERO细胞DNA降低到可接受水平（低于50 pg/剂量）。通过用VERO细胞DNA制备的探针进行斑点印迹杂交来评估剩余的细胞DNA含量。3. 最终的病毒制剂通过β-丙内酯处理灭活，效力高于2.5 IU/剂量，并能保护经脑内接种狂犬病病毒（CVS-13.2）实验感染的小鼠。4. 这种用于生产人用狂犬病疫苗的方法对于没有高科技设施的国家应该是有意义的。